The U.S. FDA granted Neuronetics Inc. clearance for use of its Neurostar advanced therapy as an adjunctive treatment of major depressive disorder in patients aged 15 to 21, making it the first transcranial magnetic stimulation treatment (TMS) cleared for this age group, the company said.
Related Keywords
, Neuronetics Inc , Bioworld Medtech , Brainsway Ltd , Magstim Co Ltd , Magnus Medical Inc , Magventure , Nexstim Oy , Transcranial Magnetic Stimulation Tms , Depression , Mmdd , Atms , 510k , Regulatory , Us , Neurology Psychiatric , Medical Devices , Fda ,
comparemela.com © 2020. All Rights Reserved.